TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06672861

Intervention type: OTHER
Group type: OTHER
Intervention: Kansas City Cardiac Dysautonomia Questionnaire (KCDysQ)
Description: To compare in patients with cardiac dysautonomia, newly developed disease specific questionnaire to established generalized SF-36 and EQ-5d questionnaires, as there are no disease specific questionnaires for comparison. These novel and established questionnaires will then be compared among groups who have relatively stable disease or stable symptoms with patients who will be expected to have a change in symptoms and QoL.

Intervention type: OTHER
Group type: OTHER
Intervention: Kansas City Cardiac Dysautonomia Questionnaire (KCDysQ)
Description: To compare in patients with cardiac dysautonomia, newly developed disease specific questionnaire to established generalized SF-36 and EQ-5d questionnaires, as there are no disease specific questionnaires for comparison. These novel and established questionnaires will then be compared among groups who have relatively stable disease or stable symptoms with patients who will be expected to have a change in symptoms and QoL.
Study: NCT06671236

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Human Polyclonal Regulatory T Cells Injection (NP001 Cell Injection)
Description: Regulatory T cell therapy, intrathecal injection
Study: NCT06517810

Intervention type: DEVICE
Intervention: QUELIMMUNE (SCD-PED)
Description: QUELIMMUNE device used as part of clinical practice.
Study: NCT05105958

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tideglusib
Description: 1000 mg/day per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tideglusib
Description: 1000 mg/day per os
Study: NCT05994157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD38-SADA:177Lu-DOTA Complex
Description: The IMP is a two-step radioimmunotherapy, delivered as two separate products CD38-SADA and 177Lu-DOTA. Both will be administered as an IV infusions.
Study: NCT06300281

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuromuscular Exercise
Description: A Neuromuscular exercise program consisting of sensorimotor system training, postural stability and control, global and local joint stabilization

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aquatic Exercise
Description: The exercise program will begin with a 10-minute warm-up period, including straight, sideways, back walking, cycling without equipment on the parallel bar, lower extremity strength exercises, standing on tiptoes and pressing on the heels, weight transfer, resistant exercises with auxiliary devices, calisthenic exercises, hamstring and quadriceps femoris stretching. It will end with a cooling period including exercises.
Study: NCT04457310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-562 (PF-06412562) 1 mg
Description: Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-562 (PF-06412562) 4 mg
Description: Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-562 (PF-06412562) 15 mg
Description: Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-562 (PF-06412562) 25 mg
Description: Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each subject will complete 5 test visits each involving the administration of CVL-562 (PF-06412562) (at different doses) or placebo. Each test visit will be separated by at least 48 hours (six half-lives of CVL-562 (PF-06412562)).
Study: NCT04529031

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reminder Focused Positive Psychiatry
Description: The focus of RFPP is on enhancing contextual discrimination and emotional regulation, and promoting the use of adaptive coping strategies in response to trauma reminders, including recognizing reminders, shifting attention from intrusive memories during exposure to reminders to a focus on positive feelings, thoughts, goals, and choices

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: attentional control condition (group process)
Description: This group process will undergo telehealth relaxation therapy twice a week for 6-week. Subjects will receive progressive muscle relaxation and other relaxation techniques as well as education about PTSD and supportive psychotherapy
Study: NCT06644716

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]F-FAPI PET-CT
Description: Each patient will receive a FAPI PET-CT.
Study: NCT06492395

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Len+DEB-TACE+HAIC
Description: For DEB-TACE, superselective catheterization is performed and DEBs loaded with pirarubicin is use for chemoembolization. The embolization end point was blood stasis of the tumor-feeding arteries. In order to reduce the risk of complications, the embolization end point was not achieved in the initial TACE but in the second or third TACE session.~After each chemoembolization, the microcatheter is reserved at the main hepatic tumor-feeding artery. The FOLFOX-based regimen is intra-arterially administered.~During follow-up, the treatment of DEB-TACE and/or HAIC will be repeated for viable tumors based on the evaluation of the follow-up laboratory and imaging examination.~Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd will be started with 7 days after the first DEB-TACE+HAIC.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Len+DEB-TACE
Description: For DEB-TACE, superselective catheterization is performed and DEBs loaded with pirarubicin is use for chemoembolization. The embolization end point was blood stasis of the tumor-feeding arteries. In order to reduce the risk of complications, the embolization end point was not achieved in the initial TACE but in the second or third TACE session. During follow-up, the treatment of DEB-TACE will be repeated for viable tumors based on the evaluation of the follow-up laboratory and imaging examination.~Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight \<60kg) P.O. qd will be started with 7 days after the first DEB-TACE+HAIC.
Study: NCT06638567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basal bolus insulin regimen
Description: Combination of long-acting and short-acting insulin in a proactive schedule for achieving better blood glucose values postoperatively
Study: NCT06637072

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efgartigimod PH20 SC
Description: Subcutaneous injection of efgartigimod PH20 SC
Study: NCT06057129

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supervised and minimally-supervised therapy with ReHandyBot
Description: During the familiarization phase at the rehabilitation clinic, participants perform one week of supervised and one week of minimally-supervised therapy with the ReHandyBot under the supervision of a supervisor (i.e., therapist or researcher). Minimally-supervised therapy means that participants try to perform therapy with the device by themselves, while the supervisor is still present but helps only in case participants encounter problems or if they have any questions. During the supervised and minimally-supervised phases (first 2 weeks), the intervention dose is 5 sessions of approximately 45 minutes per week. These sessions are performed in addition to the conventional therapy plan. During each session, the robot proposes a set of 3 exercises, each lasting between 10 and 15 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unsupervised therapy
Description: After the familiarization phase, participants train without supervision at the clinic until discharge and then at home for six weeks.~If the therapist thinks that the participant have properly learnt how to use the device and can train with it safely, the participant can keep training with the device unsupervised (both at the clinic and at home).~If participants are not ready for unsupervised therapy with the device, they receive a booklet of exercises to perform without supervision (both at the clinic and at home). These exercises do not imply the use of the robot but are exercises discussed with the therapists and meaningful for the specific patient.
Study: NCT05111249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Branaplam
Description: messenger ribonucleic acid (RNA) splicing modifier. Branaplam was administered as an oral solution once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Branaplam
Description: messenger ribonucleic acid (RNA) splicing modifier. Branaplam was administered as an oral solution once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Branaplam
Description: messenger ribonucleic acid (RNA) splicing modifier. Branaplam was administered as an oral solution once weekly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo oral solution once weekly
Study: NCT06274489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setanaxib
Description: Setanaxib (formerly GKT137831) is a first-in-class inhibitor of the human protein NADPH NOX1/4. It is a low molecular weight organic molecule and a member of the pyrazolopyridine dione chemical class.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching film-coated placebo tablets, containing only excipients
Study: NCT04933812

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Facebook discussions and Virtual group meetings
Description: Participants must join a study-specific private Facebook group and engage in discussion. Once the discussion is complete, participants have the opportunity to join virtual group sessions via Zoom
Study: NCT05004298

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animal Assited therapy
Description: The intervention will be structured in 10 group sessions, with a weekly frequency and one hour duration.
Study: NCT05830643

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social skills group psychotherapy
Description: Groups are 1.5-hours and facilitated by a psychiatrist and social worker. The groups follow Cognitive Behavioral Therapy (CBT) and the Good Lives Model (GLM). Groups involve a check-in to receive advice from group members and then revolve around 1-2 topics. The facilitators are responsible for asking probing questions about the topic to facilitate group discussion and learning.~CBT treatment involves efforts to change thinking patterns which might include: Learning to recognize one's distortions in thinking that are creating problems, and then to re-evaluate them. Gaining a better understanding of the behavior and motivation of others. Using problem-solving skills to cope with difficult situations.~GLM conceptualized healthy sexuality as the natural outcome of success in achieving life goals. Some patients have difficulty changing their self-identity from that of sex offender to that of former sex-offender. The GLM principles are helpful in achieving this aim.
Study: NCT06093191

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Natural saline inhalation
Description: Natural saline will be nebulized (5ml twice daily) with an ultrasonic nebulizer. A total of 12 weeks therapy will be scheduled.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Natural saline inhalation
Description: Natural saline will be nebulized (5ml twice daily) with an ultrasonic nebulizer. A total of 12 weeks therapy will be scheduled.
Study: NCT05830643

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adult interest group psychotherapy
Description: Groups are 1.5-hours and facilitated by a psychiatrist and social worker. The groups follow Cognitive Behavioral Therapy (CBT) and the Good Lives Model (GLM). Groups involve a check-in to receive advice from group members and then revolve around 1-2 topics. The facilitators are responsible for asking probing questions about the topic to facilitate group discussion and learning.~CBT treatment involves efforts to change thinking patterns which might include: Learning to recognize one's distortions in thinking that are creating problems, and then to re-evaluate them. Gaining a better understanding of the behavior and motivation of others. Using problem-solving skills to cope with difficult situations.~GLM conceptualized healthy sexuality as the natural outcome of success in achieving life goals. Some patients have difficulty changing their self-identity from that of sex offender to that of former sex-offender. The GLM principles are helpful in achieving this aim.
Study: NCT05389319

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prime-2-CoV_Beta
Description: 1 intramuscular injection (1.0 mL each) into the deltoid muscle on Day 1
Study: NCT05984849

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: vaccination games
Description: Brief health games to promote two different vaccines among youth

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: vaccination games
Description: Brief health games to promote two different vaccines among youth
Study: NCT06105957

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counselor Crafted Feedback
Description: Participants will receive up to 24 weekly messages that are crafted by a trained professional based on their dietary, physical activity, and weight monitoring for the week as well as their completion of online modules, to construct an individualized feedback message. The emailed feedback will provide positive reinforcement for successful goal achievement, identify possible areas for improvement, and suggest possible strategies for identified challenges.
Study: NCT04466345

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: 3 mg/day for 4 weeks, increased to 7 mg/day for 4 more weeks and titrated to 14 mg/day for the subsequent 8 weeks

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Semaglutide placebo capsules
Study: NCT04885049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Racecadotril
Description: Anti secretary
Study: NCT05680259

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maela connected follow-up
Description: Measures of pain, quality of life and health related variables (coping, self-efficacy, beliefs about pain) will be done at four times before and after surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional follow-up
Description: medical recommendations and prescriptions at hospital discharge. Measures of pain, quality of life and health related variables (coping, self-efficacy, beliefs about pain) will be done at four times before and after surgery.
Study: NCT04885049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DiaResQ Children's Powder for Suspension
Description: oral immunoglobulins
Study: NCT04618770

Intervention type: DEVICE
Group type: OTHER
Intervention: Triathlon PSR Tibial Insert
Description: The Triathlon PSR Tibial Insert is intended to be used as a component in primary TKA and is designed to reduce rotational constraint at deep flexion.
Study: NCT06349070

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Touch - Text Messaging Implementation Strategy
Description: The low touch strategy is designed as a tool to distill and organize the most important information from the Starting Early Program (StEP) original evidenced-based intervention curriculum. Video links are sent to pregnant subjects via automated SMS messaging. Subjects will receive videos (20 videos total) at least weekly lasting 17 to 31 weeks and the duration is based upon the gestational age at enrollment into the study. Subjects will also receive SMS messages in between videos at least weekly to keep them engaged and reinforce the video content delivered. The StEP curriculum is guideline concordant and includes sessions delivered during pregnancy coordinated with prenatal visits. The sessions delivered during pregnancy aim to improve diet, physical activity and stress management, enhance prenatal breastfeeding support, and build social support. The StEP curriculum was adapted into brief videos (\<5 minutes), and an additional module on Sleep Health was added.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Touch - Community Health Worker (CHW) Implementation Strategy
Description: The curriculum will be delivered by CHWs. Each subject will be asked to participate in 1-hour live sessions with a CHW. During the sessions, videos are interspersed with open-ended questions and pauses to discuss these open-ended questions. This results in an interactive session that employs principles of active learning. The curriculum includes sessions delivered during pregnancy coordinated with prenatal visits. The sessions delivered during pregnancy aim to improve diet, physical activity and stress management during pregnancy, enhance prenatal breastfeeding support, and build social support and are anchored by the same brief videos developed for the low touch strategy.
Study: NCT05003336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiangshao Granules
Description: dissolve 1 sachet (4 g) in water to be drank 3 times a day after meal for 8 weeks
Study: NCT05002153

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Description: FMT is the process of transferring stool from a healthy donor to another.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules consist a combination of agarose in normal saline/glycerol (the same vehicle as in a FMT capsules)
Study: NCT06425744

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: self-myofascial release combined reformer Pilates
Description: The self-myofascial release combined reformer Pilates group performs 10 minutes of self-myofascial release using the BALLance© method before beginning 20 minutes of Reformer Pilates. The 6-week program includes warm-up and breathing, main supine exercises 1 and 2, and movements targeting the sacroiliac and hip joints.~All Pilates exercises are designed in a variety of positions including supine, prone, sitting and standing. All participants attend twice a week for 6 weeks, for a total of 12 sessions.~And all participants performed home exercise program follows the guidelines of Geroge et al (2021) and includes myofascial release and Pilates Reformer exercises, as well as stretching exercises beneficial for chronic low back pain. The home exercises are performed three times a week for 15 minutes, and exercise materials are distributed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reformer Pilates
Description: The reformer Pilates group will do 30 minutes of Pilates on the Reformer. All Pilates exercises are designed in a variety of positions including supine, prone, sitting and standing. All participants also attend twice a week for 6 weeks, for a total of 12 sessions.~The home exercise program follows the guidelines of Geroge et al (2021) as well as stretching exercises beneficial for chronic low back pain. The home exercises are performed three times a week for 15 minutes, and exercise materials are distributed.
Study: NCT05215210

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bitter-gourd
Description: 12-week intervention of 3.6 grams of dried bitter-gourd supplements

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cucumber
Description: 12-week intervention of 3.6 grams of cucumber supplements
Study: NCT05389319

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prime-2-CoV_Beta
Description: 1 intramuscular injection (1.0 mL each) into the deltoid muscle on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prime-2-CoV_Beta
Description: 1 intramuscular injection (1.0 mL each) into the deltoid muscle on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prime-2-CoV_Beta
Description: 1 intramuscular injection (1.0 mL each) into the deltoid muscle on Day 1
Study: NCT05092581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: casirivimab+imdevimab
Description: Single dose weight-based equivalent administered intravenously (IV)
Study: NCT05197244

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culinary Medicine Intervention
Description: A 2-hour practical culinary medicine program facilitated by a culinary dietitian at a hospital-based teaching kitchen, followed by 3 virtual group follow-up sessions occurring monthly, each lasting approximately 30 minutes. The follow-up sessions will be facilitated by a culinary dietitian and will be conducted using a secure telephone/video conference platform.
Study: NCT06242483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elfie Solution
Description: The Elfie solution was designed to improve knowledge, adherence, and the quality of care for patients with cardiovascular diseases. The Elfie solution comprises a mobile phone app with the following features related to hypertension:~1. Personalized monitoring plan based on health conditions to guide frequency of monitoring of blood pressure, weight, and step count~2. Digital pillbox with daily medication-taking reminders and refill reminders~3. Clinical measurements graphs for BP, weight, medical adherence and step count~4. Newsfeed with short videos and texts related to cardiovascular diseases~5. Digital coach - Artificial intelligence technology that provides information via a chatbox as well as feedback information via personalized videos. This feature does not provide medical advice.~6. Connection with a health app or wearable for step count~7. Possibility of family peer support~8. Gamification through the Elfie rewards scoring system
Study: NCT04714359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midomafetamine HCl
Description: Initial doses per Experimental Session include 80 mg or 120 mg midomafetamine HCl, followed 1.5 to 2 hours later by a supplemental dose unless tolerability issues emerge. For an initial dose of 80 mg, a 40 mg supplemental dose will be used. For an initial dose of 120 mg, a 60 mg supplemental dose will be used. Total amounts of midomafetamine HCl to be administered per Experimental Session range from 80 mg to 180 mg.